Evidence map›Paper›PMID 35536446›Full record

ArticleInsights into imaging2022

Considerations for artificial intelligence clinical impact in oncologic imaging: an AI4HI position paper.

Luis Marti-Bonmati, Dow-Mu Koh, Katrine Riklund, Maciej Bobowicz, Yiannis Roussakis, Joan C Vilanova, Jurgen J Fütterer, Jordi Rimola, Pedro Mallol, Gloria Ribas and 4 more

Open access · goldAbstract read
In one paragraph

Article in Insights into imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 32 citations in OpenAlex.

  1. Tumor metrics imaging core labs: primer for radiologists.Abdominal radiology (New York) · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. AI for image quality and patient safety in CT and MRI.European radiology experimental · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 7 countries.

Luis Marti-BonmatiRadiology Department and Biomedical Imaging Research Group (GIBI230), La Fe Polytechnics and University Hospital and Health Research Institute, Valencia, Spain. luis_marti@iislafe.es.
Dow-Mu KohDepartment of Radiology, Royal Marsden Hospital and Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK.
Katrine RiklundDepartment of Radiation Sciences, Diagnostic Radiology, Umeå University, 901 85, Umeå, Sweden.
Maciej Bobowicz2nd Department of Radiology, Medical University of Gdansk, 17 Smoluchowskiego Str, 80-214, Gdansk, Poland.
Yiannis RoussakisDepartment of Medical Physics, German Oncology Center, 4108, Limassol, Cyprus.
Joan C VilanovaDepartment of Radiology, Clínica Girona, Institute of Diagnostic Imaging (IDI)-Girona, Faculty of Medicine, University of Girona, Girona, Spain.
Jurgen J FüttererDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Jordi RimolaCIBERehd, Barcelona Clinic Liver Cancer (BCLC) Group, Department of Radiology, Hospital Clínic, University of Barcelona, Barcelona, Spain.
Pedro MallolRadiology Department and Biomedical Imaging Research Group (GIBI230), La Fe Polytechnics and University Hospital and Health Research Institute, Valencia, Spain.
Gloria RibasRadiology Department and Biomedical Imaging Research Group (GIBI230), La Fe Polytechnics and University Hospital and Health Research Institute, Valencia, Spain.
Ana MiguelRadiology Department and Biomedical Imaging Research Group (GIBI230), La Fe Polytechnics and University Hospital and Health Research Institute, Valencia, Spain.
Manolis TsiknakisFoundation for Research and Technology Hellas, Institute of Computer Science, Computational Biomedicine Lab (CBML), FORTH-ICS Heraklion, Crete, Greece.
Karim LekadirDepartament de Matemàtiques and Informàtica, Artificial Intelligence in Medicine Lab (BCN-AIM), Universitat de Barcelona, Barcelona, Spain.
Gianna TsakouMaggioli S.P.A., Research and Development Lab, Athens, Greece.
Universitat de Barcelona · ESClínica Girona · ESFoundation for Research and Technology Hellas · GRGdańsk Medical University · PLLimassol General Hospital · CYRadboud University Medical Center · NLRoyal Marsden Hospital · GBUmeå University · SE

Funding

Horizon 2020 Framework Programme 826494Horizon 2020 Framework Programme 952103Horizon 2020 Framework Programme 952159Horizon 2020 Framework Programme 952172Horizon 2020 Framework Programme 952179
6 · The paper itself

Abstract

To achieve clinical impact in daily oncological practice, emerging AI-based cancer imaging research needs to have clearly defined medical focus, AI methods, and outcomes to be estimated. AI-supported cancer imaging should predict major relevant clinical endpoints, aiming to extract associations and draw inferences in a fair, robust, and trustworthy way. AI-assisted solutions as medical devices, developed using multicenter heterogeneous datasets, should be targeted to have an impact on the clinical care pathway. When designing an AI-based research study in oncologic imaging, ensuring clinical impact in AI solutions requires careful consideration of key aspects, including target population selection, sample size definition, standards, and common data elements utilization, balanced dataset splitting, appropriate validation methodology, adequate ground truth, and careful selection of clinical endpoints. Endpoints may be pathology hallmarks, disease behavior, treatment response, or patient prognosis. Ensuring ethical, safety, and privacy considerations are also mandatory before clinical validation is performed. The Artificial Intelligence for Health Imaging (AI4HI) Clinical Working Group has discussed and present in this paper some indicative Machine Learning (ML) enabled decision-support solutions currently under research in the AI4HI projects, as well as the main considerations and requirements that AI solutions should have from a clinical perspective, which can be adopted into clinical practice. If effectively designed, implemented, and validated, cancer imaging AI-supported tools will have the potential to revolutionize the field of precision medicine in oncology.

Indexed as

Artificial intelligenceClinical validationOncologic imagingPrediction models

Identifiers

PMID35536446
PMCPMC9091068
OpenAlexW4229456973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.